{
  "paper_id": "PMC8008631",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008631/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "RANK and RANKL are expressed in treatment-naive and anti-HER2-resistant HER2 breast cancer tumor samples. a Frequency of HER2-positive patients, treatment-naive or anti-HER2-resistant, expressing tumoral RANK or RANKL (H-score ≥ 1). The total number of patients scored for RANK or RANKL expression is indicated. b Representative images showing RANK and RANKL IHC. c Frequency of tumoral RANK-positive treatment-naive HER2 or anti-HER2-resistant patients and associations with the indicated clinicopathological parameters including those assessed by the Nottingham Grading System (histological grade and proliferation determined by mitotic count and Ki67 as detailed in [19]). The total number of patients analyzed per parameter is indicated in each case. In a and c, two-sided chi-square p values are shown when p < 0.1. n.s., non-significant (see also Fig. S1A)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8008631/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/ce69bfa7558a/13058_2021_1390_Fig1_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "RANK expression increased in HER2-positive breast cancer cell lines after treatment with anti-HER2 therapies as well as in anti-HER2-resistant cells. a\nRANK gene expression levels determined by RT-qPCR in the indicated HER2-positive cell lines after short-term treatment with lapatinib (Lapa), trastuzumab (Trastu), or the combination of both, relative to corresponding untreated cells (Ctr). Quantifications were performed in triplicates from two independent experiments. b\nRANK gene expression levels determined by RT-qPCR in SKBR3 cell lines resistant to trastuzumab (SKTR), lapatinib (SKLR), or both drugs (SKTLR, SKLTR) compared to sensitive SKBR3 parental cells. Quantifications were performed in triplicates from at least three independent experiments. c RANK protein expression in parental SKBR3 cells (SK) or resistant to trastuzumab (SKTR), lapatinib (SKLR), or both (SKLTR). β-Actin was used as a loading control. Blots shown are representative of those obtained from 3 independent experiments. d\nRANK gene expression levels in BT474 cells, either control or resistant to lapatinib (LR, according to public datasets [36]). a.u., arbitrary units. e\nRANK and RANK/NF-κB downstream gene targets BIRC3, ICAM1, TNFα, and IL8 mRNA levels relative to housekeeping gene PP1A in parental (SKBR3, BT474) and lapatinib-resistant (SKLR, BTLR) HER2-positive cell lines with or without RANKL treatment (24 h). Gene expression levels were quantified by RT-qPCR. PP1A expression was used as an internal reference gene (a, b, e). Determinations were done in triplicates, and the mean values are depicted from n ≥ 2 independent analyses. p values were calculated by ordinary one-way ANOVA (a, b) and by unpaired t tests (d) (*≤ 0.05; **≤ 0.01, ***≤ 0.001; n.s., non-significant)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8008631/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/af58d6e07426/13058_2021_1390_Fig3_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4.",
      "caption": "RANK knockdown slightly resensitizes SKLR cells to lapatinib. a The expression levels of RANK mRNA in lapatinib-resistant SKLR cells stably transduced with non-targeting (control) or two independent RANK knock-down (sh#3 and #4) vectors. RANK expression values were quantified by RT-qPCR relative to PP1A gene expression. Quantifications were performed in triplicates. b Relative number of living (relative survival) cells stably transduced with control (SKBR3 and SKLR), sh#3 or sh#4 (SKLR) and incubated for 4 days with the indicated concentrations of lapatinib. Cells were seeded in growth media; 24 h later lapatinib was added and cells were analyzed with CCK8 as detailed in the “Methods” section. The mean values and SD of four independent experiments are shown. For each experiment, data was obtained from quintuplicates. Paired t tests were done between the groups, and the two-tailed p value is depicted (**). In accordance with the lower expression of RANK achieved, sh#3 significantly reduced survival compared to SKLR control cells at 0.063 (p = 0.0097), 0.125 (p = 0.0055), and 0.25 (p = 0.0003) μM of lapatinib. For sh#4, a significant reduction in survival was observed at 0.125 μM of lapatinib (p = 0.014). The significance of relative survival was calculated for each concentration using two-tailed p values for one sample t test. c Western blot showing the levels of NF-κB (p-p65, p-IκB) and HER2 (p-HER2, p-ERK1/2, p-AKT) pathway activation in control SKBR3, lapatinib-resistant SKLR, and sh#3 SKLR cells treated with RANKL or lapatinib. Cells were serum-starved for 12 h and then treated with lapatinib (2 h) or RANKL (10 min) before processing them. Tubulin was used as a loading control (see Fig. S5B for total protein levels and Fig. S5C for relative quantifications)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8008631/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/b8b9076baf41/13058_2021_1390_Fig4_HTML.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Fig. 5.",
      "caption": "Overactivation of RANK signaling in HER2-positive cell lines increased NF-κB activation and lapatinib resistance. a Expression levels of RANK mRNA in HER2-positive SKBR3, BT474, and HCC1954 cells stably transduced with control (empty) or RANK-overexpressing (RANK) vectors. RANK expression values were quantified by RT-qPCR relative to PP1A gene expression. Experiments were performed in triplicates and standard error is depicted. b Expression levels of RANK/NF-κB downstream gene targets BIRC3, ICAM1, TNFα, and IL8 relative to PP1A gene expression in cells described in a, with and without RANKL treatment (24 h). Experiments were performed in triplicates and standard error is depicted. c Relative number of living (relative survival) SKBR3, BT474, and HCC1954 cells stably transduced with control (empty) or RANK-overexpressing (RANK) vectors incubated for 4 days with the indicated concentrations of lapatinib and/or stimulated with RANKL. Cells were seeded in growth media with/without 100 ng/ml RANKL; 24 h later, lapatinib was added and cells were analyzed with CCK8 after 4 days as detailed in the “Methods” section. A representative experiment out of three independent experiments is shown. For each experiment, data was obtained from triplicates and SD, and a two-way ANOVA p value is included. d. Western blot analyses of NF-κB (p-p65) and HER2 (p-HER2, p-ERK1/2, and p-AKT) pathway activation in cells depicted in c. Before collecting the cells, they were cultured in media without FBS for 12 h and pretreated with/without lapatinib for 2 h followed by 10 min stimulation with RANKL. Representative blots from three independent experiments are shown. Tubulin was used as a loading control (see Fig. S6B for total protein levels, Fig. S6C for quantifications and Fig. S7 for EGF/HRG stimulations)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8008631/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/e374ab1e4333/13058_2021_1390_Fig5_HTML.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Fig. 6.",
      "caption": "Co-immunoprecipitation of RANK and HER2. a Immunoprecipitation (IP) against HER2 was performed in HEK293 cells transfected with RANK-V5 and HER2, HER2-FLAG, a carboxy-terminal fragment of HER2 (611-CTF) or an amino-terminal fragment of HER2 (742-NTF). IP was performed using anti-FLAG, anti-HA, or control IgG antibodies as indicated. RANK was detected by blotting the immunoprecipitates (IP, left upper panel) or the whole lysates (input, right upper panel) with the V5 antibody. HER2 was detected in IPs (left lower panel) and input (right lower panel) using the 32H2 antibody that detects all forms of HER2. b IP against RANK-V5 was performed in HEK293 cells transfected with RANK-V5 and GFP, HER2-FLAG, a carboxy-terminal fragment of HER2 (611-CTF) or an amino-terminal fragment of HER2 (742-NTF) using the V5 antibody. In the IP and input, HER2 was detected using the 32H2 antibody. c IP against endogenous HER2 was performed in SKBR3 cells using trastuzumab (Herceptin-HCP) or a control IgG. Endogenous RANK and HER2 were detected in IP (RANK immunoprecipitated by HER2 is indicated by an asterisk (*) in the upper panel) and input samples",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8008631/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/8008631/027ecd40f30e/13058_2021_1390_Fig6_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Next, we evaluated the clinico-pathological factors associated with RANK expression in treatment-naive HER2-positive tumors (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A trend of increased frequency of RANK expression was found in ER/PR negative tumors (p = 0.170 and p = 0.090, respectively), and higher histological grade (p = 0.138) (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Similar patterns were observed in tumors resistant to anti-HER2 treatment (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Lapatinib treatment, alone or in combination with trastuzumab, resulted in higher RANK mRNA expression in SKBR3 when compared with non-treated cells (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "RANK gene and protein expression levels were significantly higher in lapatinib-resistant SKLR and dual lapatinib/trastuzumab-resistant SKLTR cells when compared to SKBR3 parental cells (Fig. 3b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Increased RANK mRNA expression was also observed in BT474 cells with acquired lapatinib resistance (LR) when compared to lapatinib-sensitive parental cells according to public datasets, platform ID: GPL570 [36]; (Fig. 3d), an increase we verified by RT-qPCR (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Lapatinib-resistant SKLR cells showed higher gene expression levels of RANK, BIRC3, ICAM1, TNFα, and IL8 compared with control SKBR3 cells, and their levels were further increased after pathway stimulation with RANKL, except for IL8 (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In these cells, BIRC3 expression did not change whereas TNFα was barely expressed (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Taken together, RANK expression increased after dual treatment with lapatinib and trastuzumab in HER2-positive human breast cancer cell lines, mimicking the results seen in breast cancer samples from the PAMELA trial (Fig. 2b).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Additionally, two HER2-positive cell lines (SKBR3 and BT474) with acquired resistance to lapatinib (SKLR and BTLR) showed increased expression of RANK and several downstream targets, when compared to their respective parental controls (Fig. 3b–e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Lapatinib treatment, alone or in combination with trastuzumab, resulted in higher RANK mRNA expression in SKBR3 when compared with non-treated cells (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "RANK gene and protein expression levels were significantly higher in lapatinib-resistant SKLR and dual lapatinib/trastuzumab-resistant SKLTR cells when compared to SKBR3 parental cells (Fig. 3b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Increased RANK mRNA expression was also observed in BT474 cells with acquired lapatinib resistance (LR) when compared to lapatinib-sensitive parental cells according to public datasets, platform ID: GPL570 [36]; (Fig. 3d), an increase we verified by RT-qPCR (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel d",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Lapatinib-resistant SKLR cells showed higher gene expression levels of RANK, BIRC3, ICAM1, TNFα, and IL8 compared with control SKBR3 cells, and their levels were further increased after pathway stimulation with RANKL, except for IL8 (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In these cells, BIRC3 expression did not change whereas TNFα was barely expressed (Fig. 3e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel e",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Taken together, RANK expression increased after dual treatment with lapatinib and trastuzumab in HER2-positive human breast cancer cell lines, mimicking the results seen in breast cancer samples from the PAMELA trial (Fig. 2b).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Additionally, two HER2-positive cell lines (SKBR3 and BT474) with acquired resistance to lapatinib (SKLR and BTLR) showed increased expression of RANK and several downstream targets, when compared to their respective parental controls (Fig. 3b–e).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 6a, RANK-V5 was detected after immunoprecipitation of HER2 or 611-CTF HER2, but not in 742-NTF or any of the control samples (IgG), indicating that RANK interacts with the carboxy-terminal region of HER2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel a",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The reverse immunoprecipitation of RANK-V5 corroborated these results (Fig. 6b).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel b",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel b",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel b",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As seen in Fig. 6c, trastuzumab precipitated endogenous RANK demonstrating that the two receptors physically interact in breast cancer cells in an EGFR-independent manner.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel c",
          "figure_key": "figure_6"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 5,
    "claims_count": 20,
    "images_downloaded": 5,
    "tables_filtered": 2
  }
}